“Significant reduction in the menopausal symptoms (as seen through Kupperman index) following 12 weeks of treatment, which was sustained throughout the 12 months of treatment.

Clinical and Experimental Obstetrics & Gynecology. 2004;31(2):123-6.

​

​

“Femarelle decreased menopausal symptoms significantly and in the same degree as Hormone Therapy (HT)”

J. Endocrinological Investigation 2013;36(7):521-6

​

​

“Treatment with Femarelle (DT56a) resulted in a significant reduction in the number and intensity of hot flushes in postmenopausal women, especially in those with frequent symptoms, and these effects were observed within the first month of treatment.”

Climacteric. 2015;18(6):813-6

​

​

“Femarelle treatment in postmenopausal women increases BMD without unwanted estrogenic effect”

Menopause. 2003;10(6):522-525

​

​

DT56a positively affects brain neurosteroidogenesis and the opiatergic system: DT56a exerts an estrogen-like effect on selective areas related to mood, cognition, and homeostasis control, presenting a specific pattern of interaction with the brain function. These findings may, in part, explain the clinical effect of DT56a on menopausal symptoms.

Menopause. 2009;16(5):1037-1043

​

​

“DT56a (Femarelle) stimulates bone formation”

British J. of Obstetrics & Gynecology. 2005;112(7):981-5

 

​

“DT56a (Femarelle®) has no effect on MCF-7 human breast cancer cell-line” 

European J. of Obstetrics & Gynecology and Reproductive Biology. 2007;130(1):140-141

​

 

“DT56a acts as a selective estrogen receptor modulator stimulating skeletal tissues without affecting the uterus”

J. of Steroid Biochemistry & Molecular Biology 2003;86(1):93-98

​

“DT56a stimulated sex-specifically female-derived osteoblasts, indicating its unique nature compared to the compounds currently used for postmenopausal osteoporosis by being bone-forming and not only an anti-resorptive agent”

Journal of Steroid Biochemistry & Molecular Biology. 2006;98(1):90-6

​

 

“The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women”

Menopause. 2011;18(3):285-8.

​

“DT56a (Femarelle), contrary to estradiol-17β, is effective in human derived female osteoblasts in hyperglycemic condition”

Journal of Steroid Biochemistry & Molecular Biology 2011;123(1-2):25-9.

​

“DT56a (Femarelle) was effective against symptomatic vulvo-vaginal atrophy in both subjective and objective measures. As expected, changes in symptoms and pH were prompt and paralleled symptomatic relief. DT56a furnished a significant improvement in Utian Quality of Life scale”

The North American Menopause Society Annual Congress 2011, book of abstracts

​

“DT56a (Femarelle), a non-hormonal botanical therapy, was shown to have the same efficacy as hormone therapy (HT)…let us offer women a first line treatment, a treatment that has the scientific foundation that we feel comfortable to recommend, which offers the necessary efficacy by targeting the estrogen receptors, while minimizing risks”

Opening Symposium: 12th European Society of Gynecology Congress, October 18, 2017; Climacteric and Menopause: from symptoms to therapies, from security to efficacy

​